MiNK Therapeutics director sells 1,500 shares

MiNK Therapeutics director Barbara Ryan reported selling a total of 1,500 shares of Common Stock in open-market transactions.

Rhea-AI Filing Summary

MiNK Therapeutics director Barbara Ryan reported selling a total of 1,500 shares of Common Stock in open-market transactions. The sales on June 4, 2026 were executed at prices of $12.7995 for 1,000 shares and $12.6835 for 500 shares. Following these transactions, she directly holds 21,969 shares of MiNK Therapeutics common stock. According to the filing, the shares sold had been received as compensation for services as a member of the company’s Board of Directors.

Insider Trade Summary

Net Seller: 1,500 shares

Net Sell 2 txns

Insider Ryan Barbara

Role Director

Sold 1,500 shs ($19K)

Type	Security	Shares	Price	Value
Sale	Common Stock	500	$12.6835	$6K
Sale	Common Stock	1,000	$12.7995	$13K

Holdings After Transaction: Common Stock — 21,969 shares (Direct)

Footnotes (1)

1. F1. The reported transaction reflects the sale of Common Stock received by Ms. Ryan as compensation for services rendered as a member of the MiNK Therapeutic Inc.'s Board of Directors.

Key Figures

Shares sold (larger trade): 1,000 shares Shares sold (smaller trade): 500 shares Total shares sold: 1,500 shares +4 more

7 metrics

Shares sold (larger trade) 1,000 shares Common Stock sold at $12.7995 on June 4, 2026

Shares sold (smaller trade) 500 shares Common Stock sold at $12.6835 on June 4, 2026

Total shares sold 1,500 shares Aggregate of two open-market sales on June 4, 2026

Sale price (larger block) $12.7995 per share Open-market sale of 1,000 Common Stock shares

Sale price (smaller block) $12.6835 per share Open-market sale of 500 Common Stock shares

Shares held after transactions 21,969 shares Direct ownership of Common Stock following the sales

Transaction date June 4, 2026 Date of both reported open-market sales

Key Terms

Common Stock, open-market sale, Form 4, Board of Directors

4 terms

Common Stock financial

"The reported transaction reflects the sale of Common Stock received by Ms. Ryan as compensation"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

open-market sale financial

"transaction_action: open-market sale, transaction_code_description: Sale in open market or private transaction"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 regulatory

"INSIDER FILING DATA (Form 4): { "issuerName": "MiNK Therapeutics, Inc.""

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Board of Directors financial

"services rendered as a member of the MiNK Therapeutic Inc.'s Board of Directors"

The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did MiNK Therapeutics (INKT) report for Barbara Ryan?

MiNK Therapeutics reported that director Barbara Ryan sold 1,500 shares of Common Stock. The Form 4 states these were open-market sales executed on June 4, 2026, and involved stock she received as board compensation.

How many MiNK Therapeutics (INKT) shares did the director sell and at what prices?

Barbara Ryan sold 1,500 MiNK Therapeutics shares. The filing shows 1,000 shares sold at $12.7995 per share and 500 shares sold at $12.6835 per share, both classified as open-market sales of Common Stock.

How many MiNK Therapeutics (INKT) shares does Barbara Ryan hold after the sale?

After the reported sales, Barbara Ryan directly holds 21,969 shares of MiNK Therapeutics Common Stock. This post-transaction holding figure is disclosed in the Form 4 and reflects her remaining direct ownership position.

What is the nature of the MiNK Therapeutics (INKT) shares sold by Barbara Ryan?

The Form 4 notes that the shares sold were Common Stock received by Barbara Ryan as compensation for her services on MiNK Therapeutics’ Board of Directors. The transaction reflects a sale of equity-based director compensation.

Were the MiNK Therapeutics (INKT) insider transactions open-market sales?

Yes. Both transactions reported for Barbara Ryan are coded as “S” for sale and described as open-market or private sales. The filing lists them as non-derivative transactions in MiNK Therapeutics Common Stock at specified per-share prices.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/05/2026 - 06:04 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ryan Barbara

(Last) (First) (Middle)

149 FIFTH AVENUE, SUITE 500

(Street)

NEW YORK NEW YORK 10010

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MiNK Therapeutics, Inc. [ INKT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	06/04/2026		S		500	D	$12.6835	22,969	D
Common Stock(1)	06/04/2026		S		1,000	D	$12.7995	21,969	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported transaction reflects the sale of Common Stock received by Ms. Ryan as compensation for services rendered as a member of the MiNK Therapeutic Inc.'s Board of Directors.

	By: /s/ Melissa Orilall as Attorney-in-Fact for Barbara Ryan	06/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)